The Morgan Welch Inflammatory Breast Cancer Research Program is committed to finding what causes inflammatory breast cancer and identifying new treatment options. We are conducting a number of treatment-based studies and a wide variety of lab based studies to understand this disease better.
Protocol 2006-1072: Inflammatory Breast Cancer (IBC)
The goal of this research study is to collect blood and tissue samples, and clinical data from patients with a diagnosis of inflammatory breast cancer who either have never received treatment (Cohort 1) or have previously received treatment (Cohort 2) for IBC. Samples and information collected from patients with IBC are very precious and critical for the researchers to learn about the disease and to find the cure for the disease. The samples will be banked at MD Anderson Cancer Center and will be used for future critical IBC researches that have been or will be approved by the MDACC Institutional Review Board. Patients’ information and privacy are protected and maintained at all times.
For information about enrolling in clinical trials contact Jie Willey, MSN, 713-792-3965 or email email@example.com.
2013-0007: Phase II study of Denosumab to define the role of bone related biomarkers in patients with breast cancer and bone metastasis
2013-0139: Phase IB trail of two folate binding protein peptide vaccine (E39 and J65) in breast and ovarian cancer patients2013-0139 Phase IB trail of two folate binding protein peptide vaccine (E39 and J65) in breast and ovarian cancer patients
2014-0464: A phase II study of BIBF-1120 (Nintedanib) for patients with HER2 normal metastatic inflammatory breast cancer
2014-0533: A phase II study of anti-PD1 (MK-3475) therapy in patients with metastatic inflammatory breast cancer who have perceived prior chemotherapy with clinical response
2014-0034: A phase II study using Talimogene Laherparepvec (T-VEC) as a single agent for IBC or non-IBC patients with inoperable local recuurence
Phase I Trials
MD Anderson has a program dedicated to the latest cutting edge therapies in testing. The Clinical Center for Targeted Therapy conducts innovative Phase I trials (early drug trials) with new drugs that may eventually improve the management of cancer. It doesn’t mean there are no other chemotherapies you can use, in fact, it's just the opposite! It usually means you are in good shape and might be a better candidate for one of the newer, more targeted therapies rather than traditional therapies.
Stem Cell Transplant
For a certain population of patients, after completing their initial therapy or if they have responding metastatic disease, stem cell transplant may be option with the goal to reduce the chance of recurrence.